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A Review of Common Drug-drug and Food-drug Interactions
Associated with Cardiovascular Medications

By Raymond Kho, Pharm.D. Candidate, Sarah Kim, Pharm.D. Candidate, Stacy Lee, Pharm.D. Candidate, and Laura Tsu,
Pharm.D., BCPS, Midwestern University College of Pharmacy - Glendale
Goal:
This home-study CPE activity has been developed to educate
pharmacists on the common drug-drug and food-drug
interactions associated with cardiovascular medications.
Objectives
1. Identify the uses of various over-the-counter (OTC) products
of interest in cardiovascular patients
2. Describe the mechanism of action (MOA) of various fooddrug/drug-drug interactions involving cardiovascular medications (statins, antiplatelet therapies, warfarin, red yeast rice)
3. Explain the clinical significance of these interactions in medication therapy
4. Relate recommendations with current clinical evidence
5. Formulate an appropriate treatment plan given a possible
drug interaction scenario for cardiovascular patients
Clopidogrel and PPIs
Clopidogrel (Plavix®) is an antiplatelet medication used to
lower the risk of ischemic events in patients who suffer from
coronary artery disease (CAD), peripheral artery disease (PAD),
or who have undergone percutaneous coronary intervention
(PCI) or coronary artery bypass grafting (CABG). As a hepatically activated prodrug, it must first be metabolized via CYP2C19
before it can take effect.1 Once activated, clopidogrel prevents
the activation of platelets by inhibiting adenosine diphosphate
(ADP) receptors, specifically P2Y12 receptors, on the platelet
surface.2 ADP is an endogenous prothrombic molecule that
is crucial for the initiation of clot formation. As shown in the
Clopidogrel in High-Risk Patients with Acute Nondisabling
Cerebrovascular Events (CHANCE) trial, clopidogrel with aspirin
in dual-antiplatelet therapy has shown added benefits in the
prevention of ischemic events in patients who suffered recent
transient ischemic attack (TIA) or minor stroke, compared to
these medications alone.3 The Clopidogrel for the Reduction of
Events During Observation (CREDO) trial found an increase in
thromboembolic protection with dual-antiplatelet therapy in
patients who had recently undergone PCI.4 Studies have also
shown a trend toward fewer ischemic strokes and heart failure
in those with non-ST elevation acute coronary syndrome taking
dual-antiplatelet therapy, as well as a decreased occurrence of
stent thrombosis compared to warfarin-aspirin therapy.5,6
Interaction
Due to the inherent bleeding concerns that accompany the use
of antiplatelet drugs and aspirin, there is legitimate controversy
over the concomitant use of these agents. Studies have shown
that there may be an increased risk of gastrointestinal (GI)
bleeding associated with clopidogrel-aspirin dual therapy and
CONTINUING EDUCATION

that proton-pump inhibitors (PPI) may be beneficial
in reducing these events.7 PPIs are known inhibitors
of CYP2C19 with differing degrees of inhibition attributed to each PPI; therefore, new concerns arise
regarding PPIs decreasing the conversion of clopidogrel to its active form and the subsequent increased
risk of thromboembolic events. Recent studies have
been performed to more clearly
elucidate the risk versus benefit of concomitant use
of PPIs in patients undergoing clopidogrel-aspirin
therapy, which have important implications for
pharmacists who may encounter this regimen in
practice.
There are studies that suggest PPIs like
omeprazole may have an effect on the activation of
clopidogrel8 and lead to increased platelet reactivity
in patients who are at risk for clots. These findings
are supported by studies that have shown that
patients using PPIs with clopidogrel suffer worse
outcomes9,10 versus those not using PPIs or PPIs
that are only slightly metabolized by CYP2C19, like
pantoprazole. From these studies, it was believed
that alternatives for CYP2C19-metabolized PPIs,
such as histamine-2-receptor antagonists or differently metabolized PPIs would provide more benefit
to patients on clopidogrel-aspirin therapy.
However, conflicting research suggests that the
pharmacodynamic interactions observed between
PPIs and clopidogrel are not universal among PPIs
and are mostly limited to omeprazole.11,12 This is
supported by the Clopidogrel and the Optimization
of Gastrointestinal Events Trial (COGENT), a randomized controlled trial that sought to investigate
the efficacy and safety of clopidogrel with PPIs in
patients receiving aspirin. Bhatt et al. found that
PPI use significantly reduced bleeding risks in these
patients and concluded that the use of omeprazole
and clopidogrel did not result in clinically significant
cardiovascular interactions7. Recent retrospective
observational reviews also paint a contradictory
picture. In their analysis, Dunn et al. found that
PPI-use in the CAPRIE study correlated with reduced
effects of clopidogrel, at least in patients who were
not also receiving aspirin, while data from the
CREDO trial showed no increase in cardiovascular
events in the PPI group.13 Currently, there is no
consensus regarding the effect PPI-use has on
outcomes in patients on dual-antiplatelet therapy
and further studies are needed to more clearly
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understand their relationship.
Recommendation
In 2010, the American College of Cardiology Foundation
(ACCF), American College of Gastroenterology (ACG), and
American Heart Association (AHA) issued a consensus
document to address the controversy regarding PPIs and
drugs like clopidogrel. The document acknowledged the
pharmacokinetic plausibility of a drug-drug interaction
involving CYP2C19 and the need for further research into
its clinical significance. For healthcare professionals, these
organizations suggest careful discretion for patients on GI
prophylaxis and antiplatelet therapies. Although PPIs are
considered appropriate in patients undergoing antiplatelet
therapy, the risks and benefits associated with
cardiovascular (CV) and GI complications must be
considered as well.14 Risk factors for GI bleed such as history
of GI bleed, advanced age, and use of corticosteroids must
be assessed, and PPI use should be reserved for those who
are at highest risk. A patient’s physician should be consulted
if concerns of negative CV outcomes outweigh the risk of
developing a GI bleed.
Niacin
Nicotinic acid (niacin) is recommended as a therapeutic
option for the treatment of dyslipidemia due to its effectiveness in favorably affecting all lipid parameters: it increases
high density lipoprotein (HDL) cholesterol by 15-35%,
decreases low density lipoprotein (LDL) cholesterol by
5-25%, and additionally decreases triglycerides (TGs) by
20-50% with doses of 2-3 g/day.15 It is thought that niacin
achieves this by working on multiple tissues, proteins, and
enzymes.16 In the liver, niacin has three functions: decrease
TG synthesis to ultimately decrease very low density lipoproteins (VLDL) and LDL secretion, inhibit removal of HDL
from circulation, and increase HDL biogenesis. Lipid-independent effects include decreased monocyte adhesion and
infiltration, increased HDL function, and decreased foam cell
formation.These effects, however, have not been conclusively shown to translate into improved clinical outcomes
in clinical trials.17, 18 In particular, the recent HPS2-THRIVE
randomized-controlled trial confirmed the results of the
AIM-HIGH trial, demonstrating no additional benefit of
adding extended release (ER) niacin and laropiprant (to
decrease flushing) to first-line therapy.19 Newly released
hyperlipidemia guidelines include this information and
recognize that lowering non-HDL-C when LDL-C is at target
levels yields no additional benefit in reducing arteriosclerotic cardiovascular disease (ASCVD) events.20 These new
guidelines focus on statin therapy, finding no data supporting the efficacy of adjunct non-statin agents in reducing
ASCVD events. Adjunct therapy with agents shown to reduce ASCVD risk in RCTs is only recommended for high-risk
individuals who have insufficient response to statins, who
cannot tolerate recommended higher statin doses, or canCONTINUING EDUCATION

not tolerate statins at all. Given the results of the HPS2THRIVE and AIM-HIGH trials, niacin may not qualify as a
non-statin alternative under these new guidelines.
Interaction
Some of niacin’s side effects stem from how its different
formulations are metabolized by the liver with first-pass
metabolism.21 Niacin is metabolized by two pathways
that result in either conjugation or amidation. The
conjugative pathway, a low-affinity and high-capacity
pathway, is only utilized when the amidation pathway
(high-affinity and low-capacity) is saturated. It is these
glycine conjugated products, such as nicotinuric acid,
that lead to prostaglandin-mediated vasodilation and
flushing. Tolerance to flushing may develop but not
before many discontinue therapy due to the discomfort.
The high-affinity and low-capacity amidation pathway
generates nicotinamide and pyrimidine metabolites
that are associated with hepatotoxicity. Hepatotoxicity
caused by niacin has been described to have an onset
of 1 week to 48 months.22 This usually presents with
elevated aminotransferase levels, but there are mixed
reports of patterns of hepatocellular and cholestatic
injury. Other effects include nausea and vomiting and a
sharp decrease in serum lipid levels, which is reversible,
with a recovery period of 1-2 months following discontinuation. Although fulminant hepatic failure is rare,
hepatotoxicity is a concern with doses exceeding 2-3 g/
day.
Niacin is available in many formulations:
immediate-release (IR), extended-release (ER) and
sustained-release (SR). Most formulations are available
as OTC supplements that have not been reviewed by
the FDA for safety and efficacy as agents for dyslipidemia, with only a few that have FDA approval.23 Since
IR products will quickly saturate the amidation pathway,
most of the IR dose will be metabolized by the conjugative pathway such that the primary side effect will be
flushing. In contrast, SR products slowly release niacin
over time which is continuously metabolized by the
amidation pathway, resulting in increased risk of hepatotoxicity. Thus, IR use is limited by extreme flushing
while SR use is limited by risk of hepatoxicity. Patients
who take IR niacin products at therapeutic doses almost
never experience hepatotoxicity, but half of those who
take SR niacin will have elevated transaminases. Niaspan®, the only available ER product, seems to be equally
metabolized by the two pathways such that it has
relatively moderate levels of flushing and hepatotoxicity.
In a clinical trial, only 5% of patients stopped therapy
due to flushing and it has not been shown to cause an
increase in aminotransferase levels at doses of 2 g/day
or lower. This middle-of-the-road product is preferable,
but currently, it is only available prescription-only.
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Recommendation
Due to the wide availability and range of niacin products
on the market, any patient taking these products should
be advised about the side effects specific to the formulation that they are taking. Patients might readily purchase
OTC niacin products without knowledge of the risks of
flushing and hepatoxicity. Given the moderate side effect
profile of Niaspan®, it would be the preferred niacin
product; however, there may be an associated increase
in cost. In addition to flushing and hepatotoxicity, niacin
is known to cause hyperglycemia so caution must also be
taken with diabetic patients. Pharmacists and physicians
should monitor for these side effects and start with lower
doses. With the recent results from clinical trials and
hyperlipidemia guidelines, it is even debatable whether
adding niacin is beneficial for decreasing clinical outcomes
in patients with dyslipidemia.
Fish Oil and Warfarin
Therapy with fish oil supplements is indicated for those
with CAD and high-dose fish oil supplements are indicated
for use in hypertriglyceridemia (AHA). Fish oils contain
the omega-3 fatty acids eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), which have potent anti-inflammatory effects stemming from their ability to inhibit
cyclooxygenase, an essential enzyme required for the
formation of prostaglandins and thromboxane.24 Reducing
inflammation, coupled with the inhibition of pro-atherosclerotic mediators25, likely account for EPA and DHA’s potent plaque stabilization characteristics. These fatty acids
are also believed to reduce triglyceride levels through numerous mechanisms including the modulation of nuclear
transcription factors associated with lipogenesis.26 Studies
are underway to further elaborate on the benefits of omega-3 fatty acids on other conditions including
rheumatoid arthritis, hypertension and depression.
Interaction
A study by Shahar et al. regarding atherosclerosis risk and
omega-3 fatty acids showed that fish oils may decrease
fibrinogen, factor VIII, and Von Willebrand factor (vWF),
as well as increase protein C.27 Fish oil’s possible interaction with platelets and clotting factors raises concern over
their potential to increase bleeding risk in patients. This
concern is further compounded when fish oils are taken
by patients who are already on antiplatelets or anticoagulants, as this may lead to severe bleeding events. In
addition to the additive anti-atherothrombic actions of
fish oils with warfarin, EPA and DHA may cause increased
bleeding due to interactions that result in decreased
platelet aggregation28, decreased platelet derived growth
factor-like proteins29, and decreased platelet activating
factor.30 In fact, increases in baseline INR have been reported in patients who have significantly increased their
CONTINUING EDUCATION

doses of fish oil to ~2g/day while taking warfarin.31
One randomized-controlled trial that included 610
subjects showed no difference in bleeding in patients
using high-dose (4g) fish oil therapy versus control.32 The
study also found no increase in bleeding time between
the two groups, though it did acknowledge that
investigation of larger doses may be warranted. The
researchers also measured plasma beta-thromboglobulin levels among the participants, which increases with
platelet activation, and found no difference between the
study and control groups. Another randomized-controlled
trial, which included patients on chronic warfarin therapy,
showed no difference in lead-in INR and treatment INR
among study groups.33 As the participants were stratified
into groups that received placebo, 3g fish oil, or 6g fish
oil, no differences in INR were noted among the different
groups. In this study, Bender et al. conclude that fish oil
supplementation of up to 3-6g/day does not significantly
affect the safety of patients taking warfarin.
Recommendation
In spite of these studies, there is not enough definitive
evidence that validates the relationship between the
use of fish oils and increased bleeding time. So how are
healthcare professionals to respond when faced with patients taking fish oil supplements along with their
antithrombic therapy? One proposed approach is to
follow the guidelines that are applicable to other anticoagulants.34 This entails the reduction of fish oil consumption or discontinuation of fish oils supplementations when
the patient is suffering from acute bleeding illnesses like
hemorrhagic stroke. Also, the discontinuation of fish oils
before surgical procedures (to decrease the risk of bleeding) and restarting these therapies following major
operations (for its antithrombotic effects) should be
considered. For all cases, it is the duty of healthcare
professionals to weigh the risks and benefits of fish oils in
patients who are at increased risk for bleeding
complications.
Red Yeast Rice
Red yeast rice (RYR) has been consumed for thousands
of years since its use as a food spice in Asia. It is prepared
by fermenting rice with the mold Monascus purpureus
(M. purpureus) under sterile and controlled conditions.
The ultimate product contains starch, sugar, sterols, isoflavones, pigments, fatty acids and, most notably, yeast
polyketides.35 These polyketides consist of monacolins
that include monacolin K, a compound that is identical
in structure to lovastatin, an HMG-CoA reductase inhibitor; hence there was a controversy over its status as an
OTC product, since it contains an FDA regulated drug.
In May 1998, the FDA took the stance that RYR supplements containing lovastatin are unapproved drugs.36 This
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was upheld by several courts and the FDA began enforcing
this edict. Currently, labels of RYR products do not contain
information on levels of lovastatin and many do not contain
lovastatin at all. Those that do are considered illegal, as
emphasized by a consumer warning issued in 2007.37
The clinical efficacy of RYR products containing lovastatin
has been demonstrated by several groups.38 In addition to
reducing total cholesterol and LDL levels, it decreases the
frequency of major coronary events. Studies have found
that RYR products containing 2-5 mg of lovastatin have
similar efficacy to 20 mg of lovastatin.39 This suggests that
there are additive and/or synergistic effects of the various
components of RYR such as isoflavonoids, monounsaturated fats, and sterols.38 There is no specified role for RYR in
updated hyperlipidemia guidelines,20 and it is briefly
mentioned as alternative or adjunct therapy in ESC/EAS
guidelines.40 Sales of RYR increased 80% between 2005 and
2008 to $20 million,36 making it vitally important for
pharmacists to be aware of its uses and limitations.
Interaction
Since RYR is defined as a dietary supplement, it is regulated
by Current Good Manufacturing Practices (cCGMP)
published by the FDA.37 These regulations not only require
that companies produce products that are consistent, but
also that they are not adulterated and correctly labeled. A
few studies validating the contents of RYR products have
been performed.
The first study conducted in 2001, analyzed nine proprietary Chinese RYR dietary supplements.41 The amount of
total monacolin K ranged widely from 0.15 to 3.37 mg/capsule. Moreover, they found citrinin, a compound that causes
kidney failure in animals and genotoxic in cultured human
lymphocytes at high doses, in seven of the nine samples.
In 2010, Gordon et al. examined these and other indices of
product purity.36 Similar to previous findings, there was a
wide variability in ingredients among the different products:
total monocolins ranged from 0.31 to 11.15 mg/capsule,
monocolin K was 0.10 to 10.09 mg/capsule, and monocolin
KA was 0.00 to 2.30 mg/capsule. Put in terms of total daily
dose following serving recommendations, this would be a
range of 2.71 to 24.71 total monacolins. Four products had
elevated levels of citrinin. The authors of the most recent
study directly contacted the FDA regarding RYR oversight.37
The FDA admitted to having no information on the number
of RYR manufacturers or distributors, and also reported
that they are not able to ensure whether these products
are consistent with cGMP regulations. These researchers
did not quantify the active ingredients in the products, but
rather looked at their labeling. They found that only 43 of 70
products had statin-related warnings, and none of the 101
products had been confirmed to pass a verification test (i.e.
USP, Consumer Labs, NSF, or NPA). Moreover, several were
combination products with other lipid-lowering agents (e.g.
CONTINUING EDUCATION

coenzyme-Q10, niacin and fish oil), vitamins (e.g. folic
acid, vitamin B6, and vitamin B12), and dietary
supplements.
In addition to the wide variability of ingredients in
RYR products, there are many safety monitoring
parameters that need to be considered. Relative to
lovastatin, RYR extracts were found to inhibit all six
CYP450 enzymes tested (CYP2B6, 2C9, 2C19, 3A4, 1A2
and 2D6) and P-glycoprotein (P-gp) to a greater
extent,39 so drug-drug interactions should be assessed.
Although most trials have found RYR to be well-tolerated, cases of myopathy, rhabdomyolysis, hepatotoxicity,
and anaphylaxis have also been reported.38, 40
Furthermore, it is considered a pregnancy category X
with documented fetal abnormalities and should be
taken with caution in patients with renal/hepatic
impairment. Lastly, since it is a yeast product, it should
not be taken if the patient is allergic to yeast products.
Recommendations
As with all supplements, great care should be taken
in helping a patient select a RYR, especially given that
there are numerous discrepancies and variability in
content. Despite the FDA’s prohibition on lovastatin-containing RYR products, they have done little to
actually regulate and enforce this. Thus, pharmacists
must be able to counsel patients inquiring about RYR,
especially about its safety concerns. Quantity and
quality may vary not only from manufacturer to manufacturer, but from batch to batch or even bottle to
bottle as well. Patients should be cautioned against its
use despite its proven efficacy, due to safety concerns
of consuming unknown amounts of a FDA approved
drug with known drug-drug interactions and side
effects. If patients have untreated dyslipidemia and are
self-medicating with RYR, they may be directed to other
OTC products or supplements that do not contain an
active drug ingredient. They should also be advised on
non-pharmacological treatment options like lifestyle
changes. The best thing an individual could do is speak
with their physician about a cost-effective FDA regulated pharmacological therapy option, with monitoring for
safety and counseling on its use.
St. John’s Wort and Statins
St. John’s wort (Hypericum perforatum) is an OTC
herbal supplement that is widely used in the U.S., and
stands as the second best-selling herbal medicine
product in the nation.43 Although a meta-analysis of 29
trials concluded that St. John’s wort extract was
superior in treating depression versus placebo44,
multiple randomized controlled trials have failed to
show its efficacy as a treatment for depression.45,46 The
current American Psychiatric Association’s guidelines
Winter 2014 • Arizona Journal of Pharmacy • 39
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for treating major depressive disorder states that St. John’s
wort is not recommended for use in treating depression, due
to the lack of evidence and regulation.47 However, St. John’s
wort is still commonly being used by the U.S. population as an
OTC self-treatment agent for depression.
St. John’s wort contains an array of compounds that
may contribute to its potential pharmacological activities,
including two compounds: hyperforin and hypericin.48 In
particular, hyperforin has been identified as an inhibitor of
several neurotransmitters including serotonin, norepinephrine, and dopamine.49 However, St. John’s wort also presents
with it an increased risk of drug-drug interactions due to the
enzyme-inducing properties associated with its natural compounds.50 Such activity may decrease the serum drug levels of
medications, thereby jeopardizing the therapeutic efficacy of
many prescription medications. One possible interaction with
St. John’s wort that has been identified in trials is associated
with HMG-CoA reductase inhibitors, also known as statins. As
statins are one of the most dispensed prescription medications
in the U.S.51, the prevalence of a drug interaction with popular
natural products like St. John’s wort is highly likely. In order to
ensure the efficacy of treatment in patients with hyperlipidemia, an assessment for possible drug interactions is
warranted in individuals who are taking statin medications.
Interaction
St. John’s wort is an inducer of both CYP3A4 and P-gp, which
are involved in the metabolism of many drugs in the human
body.52,53 This induction may be explained by St. Johns wort’s
role as a ligand for the nuclear pregnane X receptor (PXR).
Activation of the PXR increases the expression of both P-gp
and CYP3A4, so increased levels of St. John’s wort induces the
expression of P-gp and CYP3A4 in the human body.54 Another source of interaction is the natural compound hyperforin,
which has been identified as an inducer of CYP3A455, an
enzyme that is responsible for metabolizing about 50% of all
prescription medications on the market.50
Atorvastatin, simvastatin, and lovastatin have been
identified as CYP3A4 substrates56, while atorvastatin and
simvastatin are also substrates of P-gp.57 Therefore, the
concomitant use of St. John’s wort with these statin medications leads to an increase in statin metabolism, resulting in
diminished efficacy. Several studies have demonstrated the
effect of this drug interaction. (Table 1)
One randomized, double-blind study showed that taking
St. John’s wort for 2 weeks prior to taking simvastatin resulted
in a statistically significant decrease in the serum concentration and the AUC of active simvastatin metabolite.58 Another
randomized-controlled trial tested the significance of this
interaction in 16 patients with hypercholesterolemia who were
being treated with a stable dose of atorvastatin. When
atorvastatin was taken daily with St. John’s wort, statistically
significant increases were observed in both the serum LDL
and total cholesterol levels, representing a decreased efficacy
CONTINUING EDUCATION

of clinical importance.53 Another study featured 24
patients with hypercholesterolemia who were being
treated with a stable dose of simvastatin. Similar to a
previous study, concomitant use resulted in
significantly increased levels of serum LDL and total
cholesterol.59
Table 1. St. John's wort and its effect on antihyperlipidemic therapy
Sugimoto et al.58
Andren et al.53
16 healthy
16 patients with
Demographics
volunteers
hypercholesterolemia
Simvastatin
Atorvastatin
Statin
10mg x1 on day 14
10mg-40mg* daily
Dose/frequency
300mg BID
SwJ dose/frequency 300mg TID
14 days
4 weeks
Duration
Decreased serum
Increased LDL
Effect
simvastatin active
(p=0.004)
metabolite
Increased total
Decreased AUC
cholesterol (p=0.02)
(metabolite)

Eggertsen et al.59
24 patients with
hypercholesterolemia
Simvastatin
10-40mg* daily
300mg BID
4 weeks
Increased LDL
(p<0.0001)
Increased total
cholesterol
(p<0.0001)
Increased
triglycerides in
females (p=0.036)
*Indicates the stable dose of medication each patient was originally being treated with.

The increased levels of LDL and total cholesterol
demonstrated in these studies have a direct influence
on the clinical outcomes of patients who are on statin
medications. Excess LDL circulating in the blood can
get oxidized and turn into foam cells, eventually turning into atherosclerotic plaques.60 Increased plasma
concentration of oxidized LDL has also been associated
with increased risk of chronic heart disease.61 The
inadequate control of total cholesterol and LDL levels
in hyperlipidemic patients using St. John’s wort and
statins may lead to potentially life-threatening clinical
outcomes associated with the increased risk of
cardiovascular disease.
Recommendations
St. John’s wort is a popular OTC supplement which
is widely used as an alternative treatment option
for depression. However, it poses risks of numerous
drug-drug interactions as an inducer of many drug-metabolizing pathways in the human body. A pharmacist
should educate patients about the lack of consistent
evidence for the efficacy of St. John’s wort, and APA
guideline recommendations against its use as a
general treatment for treating depression.
Every patient who is on simvastatin, atorvastatin, or lovastatin must be screened for the use of St.
John’s wort. When a concomitant use is identified, the
patient must be educated about the potential drug
interactions associated with this supplement, including
the potential decrease in the control of hyperlipidemia. Because it is difficult to detect the diminished
efficacy of statin medication in a short-term period, it
is important for patients to be aware of this interaction. The patient should also be encouraged to engage
in an active conversation with the physician about the
efficacy of the statin treatment, with a possible in-
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crease in the dose of the statin medication or the initiation
of a new antidepressant.
Grapefruit Juice and Statins
While the concomitant use of two different drugs can
result in adverse events due to drug-drug interactions,
consuming certain food products while taking a medication can also influence the pharmacokinetics of drugs and
ultimately affect the clinical efficacy of the medication.
Grapefruit juice is a product that has numerous food-drug
interactions, including calcium channel blockers, CNS
modulators, and statins. Although no single constituent
has been identified as the cause of these interactions,
grapefruit juice contains many naturally-occurring compounds such as flavonoids and furanocoumarins which
have been found to have inhibitory effects on CYP3A4
and P-gp.56 The concurrent intake of statins with substances that inhibit metabolic enzymes has been shown
to increase statin serum concentration levels, which may
increase the risk of undesirable side effects such as rhabomyolysis or renal failure.
According to the new 2013 ACC/AHA guidelines,
statins are recommended as the primary pharmaceutical
therapy for treatment of blood cholesterol to reduce the
risk of ASCVD.20 The Centers for Disease Control and
Prevention’s report on prescription drug use revealed
that the use of antihyperlipidemic medications in the U.S.
doubled between 1999 and 2010.62 The trend in increased
use of statins is most likely to continue since the new ACC/
AHA guidelines greatly expanded the criteria for statin
use. As grapefruit juice and grapefruit are common foods
that are widely consumed by the public, assessment for
possible food-drug interactions is warranted for patients
who are taking statin medications.
Interaction
Several statin medications such as atorvastatin,
lovastatin, and simvastatin are metabolized through the
CYP3A4 enzyme.56 This predisposes patients that use
these medications to possible drug interactions when used
concomitantly with agents that inhibit or induce CYP3A4.
Pravastatin, fluvastatin, pitavastatin and rosuvastatin have
been shown to be metabolized by CYP3A4 at a lesser
degree63, decreasing the possible risk for interactions
with substances that affect CYP3A4. As demonstrated by
several randomized controlled studies, grapefruit juice is
one such substance that inhibits CYP3A4 in the small intestine64 and increases the plasma concentration of statins
with concomitant use. (Table 2)
The daily consumption of double-strength grapefruit
juice prior to initiating statin medications has been shown
to produce a statistically significant increase in the area
under the plasma concentration-time curve (AUC) and the
peak serum concentration (Cmax) of simvastatin,
CONTINUING EDUCATION

atorvastatin, and their active metabolites.65,66,67 Similar
results occurred in studies that used regular strength
grapefruit juice.68,69 However, trials that demonstrated
increased serum statin levels were mostly conducted
with healthy, male volunteers and not patients who were
already taking statin medications for hyperlipidemia. (Table
2) Therefore, the data is not representative of the actual
population of patients who are at risk of potential adverse
events associated with prolonged statin use.
Table 2. Effect of grapefruit juice consumption on serum statin concentration

Demographi
cs
Statin
Dose
gFJ
dose/freq
Duration
Effect

Lilja et al.67

kantola
et al.65

Lilja et
al.66

10
healthy
voluntee
rs
Lovastati
n
80mg x1
on day 3
DS
200mL
TID
3 days

10
12 healthy
healthy
volunteers
volunteers

10
20 healthy
healthy
volunteers
volunteers

8 healthy
volunteers

Simvastat
in
60mg x1
on day 3
DS
200mL
TID
3 days
Increased
Cmax,
AUC

Simvastat
in
40mgX1
on day 3
RS 200
mL daily

Atorvastat
in
10mg x1
on day 3
RS 250mL
TID

Atorvastat
in
20mg
daily
RS 250mL
TID

3 days

3 days
Increased
AUC,
Cmax
(metabolit
e)

4 days

Increase
d Cmax,
AUC

Atorvastatin
40mg x1 on
day 3
DS 200mL TID
3days
Increased
AUC,
Cmax(metaboli
te)

Lilja et
al.68

Increased
Cmax,
AUC

Fukazaw
a et al.69

Ando et
al.70

Increased
AUC

While increased blood level of statins may possibly result
in an increased risk of myopathy71, it is unclear whether a
linear relationship exists between the changes in plasma
concentration of statins and the risk of adverse events.72
Multiple variables influence the risk of such adverse
events, such as the rapid change in drug concentration,
use of other lipid-lowering therapy, and genetic factors.73
In fact, while one study utilizing daily doses of atorvastatin and grapefruit juice showed an increase in AUC of
the drug, a wide variation in the AUC of atorvastatin was
also present among the individuals in the control group
that had consumed water instead of grapefruit juice.70
The polymorphisms in CYP enzymes and transporters may
produce inherent differences in each individual’s ability
to metabolize statins74 and may account for the varying
response and efficacy of statins in different patients.
Nevertheless, an analysis of FDA Adverse Event reports
show that about 55% of all statin-associated rhabdomyolysis are suspected to be the result of drug-drug interactions75 and multiple cases of rhabdomyolysis have been
reported in patients who regularly consumed grapefruits
or grapefruit juice while they were on statin medications.76,77,78 Although it is not possible to know the exact
clinical consequence in each patient taking statins and
grapefruit juice, there is a definite risk of potentially
harmful interactions with the concomitant use.
Recommendations
In order to ensure the safety of patients taking statin
medications, each patient should be educated about
the possible drug interactions of statins and the risk of
potentially serious complications that could arise as a
result of the interactions, such as rhabdomyolysis. Before
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dispensing the medication, a pharmacist should screen the
patient’s profile for possible drug-drug interactions and talk to
the patient about the possible risk of drug-food interactions.
For patients taking simvastatin, atorvastatin, or lovastatin,
the pharmacist should ask the patient about grapefruit or
grapefruit juice consumption, and educate the patient about
the possible adverse events associated with this interaction.
In order to eliminate the risk of a possible adverse event, it
may be advisable to discourage the concomitant use of these
medications with grapefruit juice. Consuming large amounts
of grapefruit juice (more than a quart per day) while on these
medications should be discouraged in these patients.79 Statin
medications that do not confer the risk of this interaction and
thus could be considered as alternative treatment options
include pravastatin, fluvastatin, and rosuvastatin.80
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I.

CONTINUING EDUCATION QUIZ QUESTIONS
Anemia and the Role of the Pharmacist

ACPE UAN# 0100-0000-14-069-H01-P

/ 0100-0000-14-069-H01-T

1. Which of the following is not typically a
sign or symptom of chronic anemia?
a. Weakness
b. Tachycardia
c. Headache
d. Cold sensitivity

b. Fish
c. Eggs
d. Dairy
e. All of the above

2. Which medication does not decrease the
absorption of oral iron products?
a. Levothyroxine
b. Antacids
c. Cholestyramine
d. Proton pump inhibitors
3. Which of the following is true regarding
vitamin B12 deficiency?
a. Oral therapy is not preferred due to
only 10% absorption
b. Pernicious anemia, a form of B12
deficiency, is characterized by high values of
intrinsic factor
c. Replacement therapy is rarely long
term, with the issue usually resolving in 3-6
weeks
d. Though a serious outcome, neurological symptoms often resolve within a few
days of treatment if treated early on
4. Which oral iron product contains the
highest percent of elemental iron?
a. Ferrous gluconate
b. Ferrous sulfate
c. Ferrous fumarate
d. Polysaccharide-iron complex
5. Which food is/are a good source of vitamin B12?
a. Meat

6. What is the most common side effect
of oral iron therapy?
a. Headache
b. Nausea
c. Rash
d. Joint pain
7. If a patient experiences the side
effect describe above (#6) what is the
best way to try to prevent further complications?
a. Discontinue oral therapy
b. Instruct the patient to take the
tablets in one daily dose
c. Recommend the patient takes
antacids
d. Recommend the patient try taking
the tablets with orange juice

Use the following patient case for
questions 10-12:
TD is a 69 year-old female who
presents with dyspnea on exertion,
intermittent chest pain, cough and
fatigue. Her lab values at this time are
as follows:
CBC

Iron Studies

Other

Hgb 8g/dL

Serum iron 9mcg/L

MCV 72 fL/cell

Hct 26.0%

Ferritin 1 ng/mL

Reticulocyte count 3.3%

RBC 3.94 x 106
uL

TIBC 490 mcg/dL

Vitamin B12 440 pg/mL

TSAT 2%

Folic acid 6.4 mcg/L

10. What type of anemia do these lab
values indicate?
a. Iron deficiency anemia
b. Vitamin B12 deficiency anemia
c. Folate deficiency anemia
d. Pernicious anemia

8. True or False: Intravenous iron sucrose is FDA approved for the treatment
of iron-deficiency anemia

11. Which of the following would be an
appropriate treatment for TD’s condition?
a. Vitamin B12 1000mcg PO daily
b. Ferrous gluconate 300mg PO daily
c. Folic acid 0.4mg IM daily
d. Ferrous sulfate 300mg PO TID

9. Which of the following statements
about folate deficiency is false?
a. Laboratory evaluations will include
a low MCV
b. Alcoholism is a risk factor
c. Green leafy vegetables are a good
source of folate
d. Irritability and memory
impairment can be symptoms

12. Which of the following statements is
false regarding TD’s therapy?
a. Taking her medication with orange
juice will increase its absorption
b. It is expected that TD’s Hgb should
increase by 5g/ dL per week
c. TD may experience dark stools
d. Eating meat and beans could help
aid in her treatment

II. A Review of Common Drug-drug and Food-drug Interactions Associated with Cardiovascular Medications
ACPE UAN# 0100-0000-14-070-H01-P / 0100-0000-14-070-H01-T

1. What is the concern regarding
concomitant use of PPIs and clopidogrel?
a. PPIs and clopidogrel present a
duplication of therapy
b. PPIs may inhibit the activation of
clopidogrel causing increased CV risks
c. PPIs may cause increased hepatic
elimination of clopidogrel causing
increased CV risks
d. Toxic accumulation of PPIs may
occur because clopidogrel are also
metabolized by CYP2C19.

2. Which of the following medications
used for the regulation of gastric acid
production presents the most concern
when used with antiplatelet agents
like clopidogrel?
a. Omeprazole
b. Pantoprazole
c. Ranitidine
d. Famotidine
3. An elderly patient with a history
of GI bleed presents to the pharmacy
to refill his Plavix. He has a history of

CVD and just underwent surgery for placement of
a coronary stent a week ago. You notice that he is
taking Plavix with aspirin, as well as pantoprazole
for bleeding prophylaxis. Your response should be:
a. Consult the prescribing physician, as you
should with every case taking PPIs and dual-antiplatelet therapy
b. Advise the patient to space out the dosing of
his PPI, at least 4 hours apart from his antiplatelet
medications
c. Call the hospital. The patient is at high risk of a
sudden CV event
d. Refill the Plavix because PPIs are indicated in
this patient based on his risk for GI bleed.

CONTINUING EDUCATION QUIZ QUESTIONS CONTINUED

A Review of Common Drug-drug and Food-drug Interactions Associated with Cardiovascular Medications
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4. Which of the following contributes to the
concern over fish oil supplementation in
conjunction with warfarin therapy?
a. The cost of fish oil supplementation and
warfarin therapy would be excessive
b. Fish oils would inhibit the effects of
warfarin therapy
c. Omega-3 fatty acids may decrease
fibrinogen, factor VIII, and Von Willebrand
factor (vWF), which may increase risk of
bleeding
d. Omega-3 fatty acids may decrease
protein C, which may increase risk of
bleeding
5. Fish oils show benefit in reducing
atherosclerosis because of their ability to
a. Inhibit cyclooxygenase
b. Increase prostaglandins and
thromboxane
c. Decrease platelet aggregation
d. Modulate nuclear transcription factors
6. Patient YL has been recently discharged
from the hospital following valve
reconstruction surgery. She would like to
continue taking her fish oil supplements for
her high triglyceride levels. How would you
respond to her?
a. She can no longer take her fish oil
supplements due to its ability to increase
bleeding risk
b. She can no longer take her fish oil
supplements because they will no longer be
effective
c. She no longer needs fish oil
supplementation because she had
major heart surgery
d. She can restart her fish oil
supplements once she is cleared by her
physician
7. What is the possible explanation for the
drug interaction between statin drugs and
grapefruit juice?
a. Grapefruit juice is an inducer of the
enzyme that metabolizes statins
b. Grapefruit juice worsens hyperlipidemia
in patients taking statin medications
c. Grapefruit juice is an inhibitor of the
enzyme that metabolizes certain statins.
d. Grapefruit juice is an inhibitor of the
enzyme that matabolizes all statins.
8. Mrs. Jones is a 55 year-old female who
was prescribed a new drug regimen for her
CONTINUING EDUCATION

hyperlipidemia. (Simvastatin 20mg PO
daily). However, after watching Dr. Oz
talk about drug side effects on TV last
night, she is hesitant to take her medication and asks for your opinion. What
would you tell her?
a. Statins are known to be safe
medications with no significant drug
interations
b. Statins are associated with side effects involving muscle pain and disorder
c. Drinking large quantities of grapefruit juice regularly while on this
medication could result in a rare but
serious muscle disorder
d. B and C
9. According to new hyperlipidemia
guidelines, niacin would be recommended to treat hyperlipidemia for
which of the following patient populations?
a. First-line for a patient newly
diagnosed with dyslipidemia
b. With elevated non-HDL-C and at
target LDL-C to reduce ASCVD outcomes
c. With high-risk and intolerant to
statin therapy
d. Not recommended given the lack of
support in clinical trials
10. Which statement is correct about
niacin formulations?
a. IR products are associated with
hepatotoxicity
b. Niaspan is the only FDA approved
ER product and has relatively moderate
risks of hepatotoxicity and flushing
c. SR products are associated with
flusing
d. All formulations (IR, SR, and ER) are
available OTC.
11. RYR is a dietary supplement that
a. Is actively regulated by the FDA because it contains a FDA regulated drug
b. Is considered to be illegally marketed if it contains monacolin K
c. Has been found to have consistent
levels of active ingredients
d. Is recommended as an alternative
or adjunct therapy in updated
hyperlipidemia guidelines.
12. A woman approaches you stating
she heard RYR is a natural product that

could help with her cholesterol. She is
currently not taking anything for hyperlipidemia due to finances. What should
be a justified recommendation?
a. Yes, take RYR because it contains a
FDA regulated drug used for hyperlipidemia
b. Yes, tkae RYR but only purchase a
product with consistent levels of monacolin K
c. No, do not take RYR because it has
not been shown to be effective
d. No, taking RYR is not recommended due to quality concerns as well as
safety concerns
13. Mrs. Young is a 50-year old female
who is taking Atorvastatin 20mg PO
daily for hyperlipidemia. After talking
to her, you discover that she is also
taking a daily dose of St. John’s word
600mg for depression. What is (are) the
appropriate counseling point(s) for Mrs.
Young?
a. St. John’s wort is a safe and effective, FDA-approved treatment for
depressive disorders
b. There is a risk of potentially harmful
drug interaction if atorvastatin is used
with St. John’s wort
c. St. John’s wort may decrease the
efficacy of atorvastatin
d. B and C.
14. What is the possible explanation for
the interaction between St. John’s wort
and Statin drugs?
a. St. John’s wort is an inducer of
CYP3A4 and P-gp
b. St. John’s wort is a competitive
inhibitor of statin drugs
c. St. John’s wort is an inhibitor of
CYP3A4 and P-gp
d. Statins enhance the therapeutic
effect of St. John’s wort
15. What is a possible adverse drug
event associated with the consumption
of large quantities of grapefruit juice on
statin therapy?
a. Rhabdomyolysis
b. Stevens-Johnson Syndrome
c. Reye Syndrome
d. Acute pancreatitis
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